Fairvalue-Calculator Fairvalue-Calculator
EN DE

RemeGen Co (REGMF) Fair Value & Analysis

Healthcare · US · Market cap $6.8B

Price$12.05
Fair Value$3.96
Upside-67.1%
Quality93/100
Evidence: High Range $2.97 – $7.51

Fair value as of: Jun 24, 2026

Analysis

RemeGen Co (REGMF) currently trades at $12.05, while our model-based Fair Value estimate is $3.96 — implying the stock looks roughly 67.1% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is RemeGen Co (REGMF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $3.96 versus a price of $12.05 — about −67% (overvalued). Model-based estimate, not financial advice.
What is the fair value of REGMF?
Our 21-model fair value for RemeGen Co is $3.96 (as of Jun 24, 2026), built from audited fundamentals. The current price is $12.05.
What is the quality score of REGMF?
RemeGen Co has a Quality Score of 93/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.